Tesamorelin

Tesamorelin – Educational Overview

For Informational & Research Purposes Only.

What Is Tesamorelin?

Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH). It is designed to stimulate the pituitary gland to increase the natural secretion of growth hormone (GH), which in turn may influence metabolic processes, body composition, and lipid regulation.

Tesamorelin has been studied primarily in clinical settings for its effects on reducing visceral adipose tissue in specific populations.

Mechanism of Action (Scientific Context)

Tesamorelin binds to GHRH receptors in the anterior pituitary gland, leading to:

• Increased pulsatile secretion of growth hormone (GH)

• Elevation of insulin-like growth factor 1 (IGF-1) levels

• Downstream effects on lipid metabolism and body fat distribution

Unlike direct GH administration, Tesamorelin stimulates the body’s own GH production, which can preserve natural regulatory feedback mechanisms.

Clinical Research Background

Tesamorelin has been investigated in clinical trials for:

• Reducing visceral adipose tissue in adults with HIV-associated lipodystrophy

• Potential effects on body composition and metabolism

• Studying GH axis function and endocrine regulation

While it has an FDA-approved indication for HIV-associated lipodystrophy under the brand name Egrifta, its broader applications are still under research.

Important Note

This page is provided for educational and scientific purposes only.

• Tesamorelin is not approved for non-FDA indications or experimental use outside regulated clinical trials.

• Its investigational use should be limited to qualified research environments under regulatory oversight.